Boston Scientific Co. (NYSE:BSX) Stock Position Decreased by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. lowered its position in Boston Scientific Co. (NYSE:BSX) by 1.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 267,743 shares of the medical equipment provider’s stock after selling 3,513 shares during the period. Braun Stacey Associates Inc.’s holdings in Boston Scientific were worth $23,915,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Creative Planning lifted its position in shares of Boston Scientific by 7.7% in the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock worth $17,113,000 after buying an additional 14,663 shares during the last quarter. Global Retirement Partners LLC raised its stake in shares of Boston Scientific by 11.5% in the 3rd quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider’s stock valued at $366,000 after acquiring an additional 449 shares in the last quarter. Stratos Wealth Advisors LLC lifted its holdings in Boston Scientific by 8.9% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider’s stock worth $538,000 after purchasing an additional 522 shares during the last quarter. Blue Trust Inc. boosted its position in Boston Scientific by 91.6% during the third quarter. Blue Trust Inc. now owns 10,492 shares of the medical equipment provider’s stock worth $808,000 after purchasing an additional 5,017 shares during the period. Finally, Capital Investment Advisors LLC acquired a new position in Boston Scientific during the third quarter valued at approximately $217,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.1 %

Shares of BSX opened at $106.20 on Tuesday. The business’s 50 day simple moving average is $96.44 and its 200-day simple moving average is $88.39. Boston Scientific Co. has a one year low of $65.33 and a one year high of $107.17. The company has a market capitalization of $156.51 billion, a P/E ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the sale, the chief financial officer now owns 241,451 shares in the company, valued at $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 87,326 shares of company stock valued at $8,673,948. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BSX. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. Citigroup upped their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Stifel Nicolaus lifted their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Mizuho increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Finally, Piper Sandler upped their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.